title: Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
abstract: BACKGROUND
  High-dose methotrexate (HD-MTX) is one of the most important agents in the therapy of osteosarcoma (OSC). Acute and delayed toxicities still constitute clinical problems. Methylenetetrahydrofolate reductase (MTHFR) has a key role in the folate cycle. In case of homozygosity of the 677C-->T polymorphism, treatment with antimetabolites, such as MTX, can cause additional toxicity.
  
  
  METHODS
  In the present work, we describe the case of a 10-year-old boy with OSC. After the first HD-MTX infusion (12 g/m2/6 h) acute neurological disturbances were detected followed by severe hepatotoxicity. Plasma concentrations of MTX and 7-OH-MTX showed delayed clearance. Calcium folinate was administered to the patient until +186 hours. Tha patient was homozygous for the 677 polymorphism and wild-type for the 1298 polymorphism of the MTHFR gene.
  
  
  CONCLUSIONS
  We hypothesize that MTX toxicity can be explained by the association between homozygosity of the MTHFR C677T polymorphism causing disturbances in the folate status and thus an enhanced vulnerability of the central nervous system to antimetabolites and to the prolonged MTX exposure due to delayed MTX clearance.
authors.affiliation: Second Department of Pediatrics, Semmelweis University, H-1094 Budapest, Hungary. muller@gyer2.sote.hu
authors.forename: Judit
authors.initials: J
authors.lastname: Müller
authors.forename: Judit
authors.initials: J
authors.lastname: Kralovánszky
authors.forename: Vilmos
authors.initials: V
authors.lastname: Adleff
authors.forename: Eva
authors.initials: E
authors.lastname: Pap
authors.forename: Krisztina
authors.initials: K
authors.lastname: Németh
authors.forename: Viktor
authors.initials: V
authors.lastname: Komlósi
authors.forename: Gábor
authors.initials: G
authors.lastname: Kovács
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D002648:Child; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics* / Q000378:metabolism; D020258:Neurotoxicity Syndromes / Q000209:etiology* / Q000378:metabolism; D012516:Osteosarcoma / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D011110:Polymorphism, Genetic
chemical_list: D000964:Antimetabolites, Antineoplastic; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D008727:Methotrexate